Cardiovascular Drugs Practice Questions

Q: Which of the following conditions is a contraindication for the use of beta-blockers?

Peripheral vascular disease. **Explanation:** **Why Peripheral Vascular Disease (PVD) is the Correct Answer:** Beta-blockers, particularly non-selective ones (like Propranolol), are contraindicated in PVD because they block **$\beta_2$ receptors** in the skeletal muscle vasculature. Normally, $\beta_2$ stimulation causes vasodilation. When these receptors are blocked, the **$\alpha_1$-mediated vasoconstrictor tone** remains unopposed. This leads to further narrowing of peripheral blood vessels, worsening symptoms like intermittent claudication, and potentially precipitating critical limb ischemia or Raynaud’s phenomenon. **Why the Other Options are Incorrect:** * **Angina:** Beta-blockers are a first-line treatment for stable angina. They reduce myocardial oxygen demand by decreasing heart rate and contractility. * **Hypertension:** They are standard antihypertensive agents, especially in patients with co-existing conditions like post-myocardial infarction or heart failure. * **Anxiety:** Beta-blockers (specifically Propranolol) are used to manage the peripheral autonomic symptoms of performance anxiety, such as palpitations and tremors. **NEET-PG High-Yield Clinical Pearls:** 1. **Cardioselectivity:** If a beta-blocker must be used in mild PVD, **$\beta_1$-selective blockers** (e.g., Atenolol, Metoprolol) or those with vasodilatory properties (e.g., **Nebivolol, Carvedilol**) are preferred as they have less effect on peripheral $\beta_2$ receptors. 2. **Absolute Contraindications:** Always remember the "ABCDE" of beta-blocker contraindications: **A**sthma/COPD, **B**lock (Heart block), **C**ardiogenic shock, **D**ecompensated heart failure, and **E**xtremity issues (Severe PVD/Raynaud's). 3. **Diabetes:** Beta-blockers can mask the warning signs of hypoglycemia (tachycardia) and should be used cautiously in diabetics.

Q: Which calcium channel blocker has predominant peripheral effects?

Amlodipine. **Explanation:** Calcium channel blockers (CCBs) are categorized into two main chemical classes based on their site of action and clinical effects: **Dihydropyridines (DHPs)** and **Non-dihydropyridines**. **Why Amlodipine is correct:** Amlodipine belongs to the **Dihydropyridine** class. These drugs have a high affinity for the L-type calcium channels located in the **vascular smooth muscle** rather than the myocardium. By blocking these channels, they cause potent peripheral vasodilation, making them highly effective for treating hypertension and chronic stable angina. Because they have minimal effect on the heart's conduction system at clinical doses, their effects are considered "predominantly peripheral." **Why the other options are incorrect:** * **Verapamil (Phenylalkylamine):** This is a non-dihydropyridine CCB with a high affinity for calcium channels in the **myocardium**. It has significant negative inotropic (contractility) and negative dromotropic (conduction) effects. It is primarily used for arrhythmias (PSVT) and has the least peripheral effect among CCBs. * **Diltiazem (Benzothiazepine):** This is also a non-dihydropyridine that occupies a middle ground. It acts on both the heart and the blood vessels, but its cardiac depressant effects are more clinically significant than its peripheral effects compared to DHPs. **High-Yield Clinical Pearls for NEET-PG:** * **Amlodipine Side Effect:** The most common side effect is **ankle edema** (due to preferential precapillary dilatation). * **Drug of Choice:** Verapamil is a drug of choice for prophylaxis of cluster headaches and rate control in atrial fibrillation. * **Nimodipine:** A DHP specifically used to prevent cerebral vasospasm following subarachnoid hemorrhage. * **Clevidipine:** An ultra-short-acting IV DHP used in hypertensive emergencies.

Q: A 50-year-old male presents with malignant hypertension. What is the drug of choice for its management?

Sodium nitroprusside. **Explanation:** **Sodium Nitroprusside** is the drug of choice for hypertensive emergencies (malignant hypertension) because of its rapid onset of action (seconds) and short duration of action (1–2 minutes). It is a potent balanced vasodilator that acts by releasing nitric oxide (NO), which stimulates guanylyl cyclase to increase cGMP, leading to the relaxation of both arteriolar and venous smooth muscles. This allows for precise, minute-to-minute titration of blood pressure in an ICU setting. **Why other options are incorrect:** * **Sublingual Nifedipine:** Previously used, it is now **contraindicated** in hypertensive emergencies. It causes an unpredictable, precipitous drop in blood pressure, which can trigger reflex tachycardia and sympathetic activation, potentially leading to myocardial infarction or stroke. * **Furosemide:** While it helps in cases of hypertension associated with fluid overload (e.g., acute heart failure), it is not the primary agent for lowering systemic vascular resistance in malignant hypertension. * **Enalapril:** As an ACE inhibitor, its onset is too slow for emergency management, and its effect can be unpredictable in patients who are volume-depleted or have high renin levels. **NEET-PG High-Yield Pearls:** * **Cyanide Toxicity:** Prolonged infusion of Nitroprusside can lead to cyanide accumulation. The antidote is **Sodium Thiosulfate** or **Hydroxocobalamin**. * **Light Sensitivity:** Nitroprusside solution is unstable in light; the IV bottle must be covered with opaque foil. * **Alternative:** **Labetalol** (alpha + beta blocker) is often preferred in clinical practice today, especially in aortic dissection and pregnancy-induced hypertension (Eclampsia). * **Fenoldopam:** A dopamine $D_1$ agonist used in hypertensive emergencies, particularly beneficial in patients with renal impairment.

Q: Which of the following prostaglandin analogues is used in transposition of great vessels to keep the ductus arteriosus patent?

Alprostadil (PGE1). **Explanation:** The correct answer is **Alprostadil (PGE1)**. **1. Why Alprostadil is correct:** In certain cyanotic congenital heart diseases, such as **Transposition of the Great Vessels (TGA)**, Tetralogy of Fallot, or Pulmonary Atresia, the infant’s survival depends on maintaining a connection between the systemic and pulmonary circulations. The **Ductus Arteriosus** normally closes shortly after birth due to a drop in prostaglandin levels. **Alprostadil**, a synthetic PGE1 analogue, is administered via continuous intravenous infusion to prevent this closure (maintain patency), allowing for adequate oxygenation of the blood until surgical intervention can be performed. **2. Why other options are incorrect:** * **Misoprostol (PGE1):** While also a PGE1 analogue, it is primarily used for **NSAID-induced peptic ulcers** and as an **abortifacient** (in combination with Mifepristone) or for postpartum hemorrhage. It is administered orally or vaginally, not IV for ductal patency. * **Bimatoprost (PGF2α):** This is a prostamide analogue used topically in the treatment of **glaucoma** (to increase uveoscleral outflow) and for eyelash hypotrichosis. * **Dinoprostone (PGE2):** This is primarily used in obstetrics for **cervical ripening** and induction of labor. **High-Yield Clinical Pearls for NEET-PG:** * **PDA Maintenance:** Alprostadil (PGE1) keeps the ductus **O**pen. * **PDA Closure:** NSAIDs like **Indomethacin** or **Ibuprofen** (non-selective COX inhibitors) are used to **C**lose a Patent Ductus Arteriosus by inhibiting prostaglandin synthesis. * **Side Effect:** A common side effect of Alprostadil infusion in neonates is **apnea**, necessitating close respiratory monitoring. * **Alprostadil** is also used in the treatment of erectile dysfunction (intracavernosal injection).

Q: Which of the following is NOT a contraindication for the use of digoxin?

Hyperkalemia. **Explanation:** Digoxin is a cardiac glycoside that inhibits the Na+/K+-ATPase pump. Understanding its contraindications is crucial for NEET-PG, as it has a narrow therapeutic index. **Why Hyperkalemia is the Correct Answer:** Hyperkalemia is **not** a contraindication; in fact, **Hypokalemia** is the major contraindication. Potassium and digoxin compete for the same binding site on the Na+/K+-ATPase pump. When potassium levels are low (hypokalemia), more digoxin binds to the pump, leading to digoxin toxicity. Conversely, hyperkalemia antagonizes the actions of digoxin. Notably, digoxin is used with caution in renal failure (where hyperkalemia occurs), but the electrolyte state itself does not prohibit its use. **Analysis of Incorrect Options:** * **Acute Rheumatic Carditis:** Digoxin is contraindicated here because the inflamed myocardium is highly sensitive to digitalis, significantly increasing the risk of drug-induced arrhythmias. * **Thyrotoxicosis:** In hyperthyroid states, there is a high-output state and increased sympathetic activity. Digoxin is relatively ineffective and can predispose the patient to arrhythmias due to the hypermetabolic state of the heart. * **WPW Syndrome:** Digoxin is strictly contraindicated. It shortens the refractory period of the accessory pathway (Bundle of Kent) while slowing AV node conduction. This can lead to a rapid ventricular rate and potentially fatal ventricular fibrillation. **High-Yield Clinical Pearls:** * **Antidote:** Digibind (Digoxin-specific antibody fragments). * **ECG Changes:** Characterized by the "Reverse Tick" sign or "Sagging" ST-segment depression. * **Toxicity Marker:** The most common arrhythmia in toxicity is **PVCs** (Premature Ventricular Contractions); the most characteristic is **PAT with block** (Paroxysmal Atrial Tachycardia with AV block). * **Electrolyte Triad:** Toxicity is precipitated by **Hypokalemia, Hypomagnesemia, and Hypercalcemia.**

Q: Mephenteramine can be used in hypovolemic shock, although intravenous fluid supplementation is primary treatment. It acts by:

All of the above. **Explanation:** Mephentermine is a **mixed-acting sympathomimetic** amine. It acts both directly by stimulating adrenergic receptors and indirectly by releasing endogenous norepinephrine from nerve endings. Its pharmacological profile makes it a potent cardiovascular stimulant. **Why "All of the above" is correct:** Mephentermine acts on both **$\alpha$ and $\beta$ receptors**, leading to a multi-faceted hemodynamic response: 1. **Increasing Cardiac Output (Option A):** Through its $\beta_1$-agonist action, it exerts positive inotropic (increased force) and chronotropic (increased rate) effects, thereby increasing the total cardiac output. 2. **Increasing Systolic Blood Pressure (Option B):** The increase in cardiac output directly elevates the systolic blood pressure (SBP). 3. **Increasing Diastolic Blood Pressure (Option C):** Through its $\alpha$-agonist action, it causes peripheral vasoconstriction, which increases systemic vascular resistance (SVR), leading to a rise in diastolic blood pressure (DBP). **Why individual options are insufficient:** While options A, B, and C are individually correct, they only describe a partial effect of the drug. Since Mephentermine simultaneously improves contractility and vascular tone, it raises all three parameters, making "All of the above" the most accurate clinical description of its action. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Use:** It is most commonly used to prevent or treat **hypotension following spinal anesthesia**. * **Hypovolemic Shock:** While it can support BP, it is **never** the first-line treatment; aggressive IV fluid resuscitation remains the priority. * **CNS Effect:** It has mild CNS stimulant properties (similar to amphetamines) but is much less potent. * **Metabolism:** It is not metabolized by MAO; hence, it has a longer duration of action compared to catecholamines.

Q: Long-acting calcium channel blockers act during which phase of the action potential?

Phase 2. **Explanation:** The correct answer is **Phase 2 (Plateau Phase)**. In the cardiac action potential of non-pacemaker cells (ventricular myocytes), **Phase 2** is characterized by a "plateau." This phase occurs due to a delicate balance between the inward movement of **Calcium ions (Ca²⁺)** through **L-type calcium channels** and the outward movement of Potassium ions (K⁺). Calcium channel blockers (CCBs), such as Verapamil, Diltiazem, and Amlodipine, specifically inhibit these L-type channels. By reducing the inward calcium current during this phase, CCBs shorten the plateau duration and decrease cardiac contractility (negative inotropy). **Analysis of Incorrect Options:** * **Phase 0 (Depolarization):** In ventricular cells, this is driven by the rapid influx of **Sodium (Na⁺)** via fast voltage-gated Na⁺ channels. (Note: CCBs do act on Phase 0 in *pacemaker* cells, but standard CCB pharmacology questions refer to the ventricular plateau). * **Phase 1 (Early Repolarization):** This brief phase is caused by the inactivation of Na⁺ channels and the transient outward flow of **K⁺ ions**. * **Phase 3 (Rapid Repolarization):** This phase is dominated by the massive efflux of **K⁺ ions** through delayed rectifier channels, bringing the membrane potential back to resting levels. **Clinical Pearls for NEET-PG:** * **Class IV Antiarrhythmics:** CCBs (Verapamil/Diltiazem) are classified here; they primarily slow conduction through the AV node by affecting the calcium-dependent upstroke in nodal tissue. * **Dihydropyridines (e.g., Amlodipine):** These are "long-acting" and more selective for vascular smooth muscle, used primarily for hypertension. * **Contractility:** Because Phase 2 provides the calcium necessary for **Calcium-Induced Calcium Release (CICR)** from the sarcoplasmic reticulum, CCBs significantly impact the force of contraction.

Q: Which one of the following drugs is most likely to block K+ channels in the heart responsible for the delayed rectifier current?

Amiodarone. **Explanation:** The question tests the classification of antiarrhythmic drugs based on the **Vaughan-Williams classification**. **Why Amiodarone is Correct:** Amiodarone is a **Class III antiarrhythmic agent**. The primary mechanism of Class III drugs is the blockade of **potassium (K+) channels**, specifically the **delayed rectifier current ($I_{Kr}$)** [2]. By blocking these channels during Phase 3 of the cardiac action potential, Amiodarone prolongs the action potential duration (APD) and the effective refractory period (ERP) [2]. While Amiodarone has Class I, II, and IV activities, its K+ channel-blocking effect is its defining Class III characteristic. **Why the Other Options are Incorrect:** * **Encainide (Option B):** This is a **Class IC** agent. Its primary action is the potent blockade of fast sodium (Na+) channels (Phase 0), significantly slowing conduction velocity with minimal effect on the action potential duration [1]. * **Lidocaine (Option C):** This is a **Class IB** agent. It blocks Na+ channels in the inactivated state and actually tends to *shorten* the action potential duration, rather than blocking K+ channels. * **Phenytoin (Option D):** Also classified as a **Class IB** antiarrhythmic, it is primarily used for digitalis-induced arrhythmias. Like lidocaine, it blocks Na+ channels and does not target the delayed rectifier K+ current. **High-Yield NEET-PG Pearls:** * **Amiodarone Side Effects:** Pulmonary fibrosis, hypothyroidism/hyperthyroidism (due to high iodine content), corneal microdeposits, and "blue-gray" skin discoloration. * **ECG Changes:** Class III agents typically cause **QT interval prolongation**, which carries a risk of *Torsades de Pointes* [2] (though this risk is lower with Amiodarone compared to Sotalol). * **Pure Class III:** While Amiodarone is mixed, **Dofetilide and Ibutilide** are considered "pure" K+ channel blockers.

Question 1

Which of the following conditions is a contraindication for the use of beta-blockers?

Accepted Answer

Peripheral vascular disease

Answer

Angina

Answer

Hypertension

Answer

Anxiety

Question 2

Which calcium channel blocker has predominant peripheral effects?

Accepted Answer

Amlodipine

Answer

Verapamil

Answer

Diltiazem

Answer

None of these

Question 3

Tadalafil acts on Phosphodiesterase 5 and causes accumulation of?

Accepted Answer

cGMP

Answer

cAMP

Answer

PAF

Answer

IL 10

Question 4

A 50-year-old male presents with malignant hypertension. What is the drug of choice for its management?

Accepted Answer

Sodium nitroprusside

Answer

Sublingual nifedipine

Answer

Furosemide

Answer

Enalapril

Question 5

Which of the following prostaglandin analogues is used in transposition of great vessels to keep the ductus arteriosus patent?

Accepted Answer

Alprostadil (PGE1)

Answer

Misoprostol (PGE1)

Answer

Bimatoprost (PGF2)

Answer

Dinoprostone (PGE2)

Question 6

Which of the following is NOT a side-effect of captopril?

Accepted Answer

Hemolytic anemia

Answer

Cough

Answer

Hyperkalemia

Answer

Renal dysfunction

Question 7

Which of the following is NOT a contraindication for the use of digoxin?

Accepted Answer

Hyperkalemia

Answer

Acute rheumatic carditis

Answer

Thyrotoxicosis

Answer

WPW syndrome

Question 8

Mephenteramine can be used in hypovolemic shock, although intravenous fluid supplementation is primary treatment. It acts by:

Accepted Answer

All of the above

Answer

Increasing cardiac output

Answer

Increasing systolic blood pressure

Answer

Increasing diastolic blood pressure

Question 9

Long-acting calcium channel blockers act during which phase of the action potential?

Accepted Answer

Phase 2

Answer

Phase 0

Answer

Phase 1

Answer

Phase 3

Question 10

Which one of the following drugs is most likely to block K+ channels in the heart responsible for the delayed rectifier current?

Accepted Answer

Amiodarone

Answer

Encainide

Answer

Lidocaine

Answer

Phenytoin

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?